Compare BH & IVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BH | IVA |
|---|---|---|
| Founded | 1934 | 2011 |
| Country | United States | France |
| Employees | 2359 | 77 |
| Industry | Restaurants | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 971.1M | 883.8M |
| IPO Year | N/A | N/A |
| Metric | BH | IVA |
|---|---|---|
| Price | $323.47 | $3.82 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 10 |
| Target Price | N/A | ★ $16.20 |
| AVG Volume (30 Days) | 65.0K | ★ 527.0K |
| Earning Date | 05-04-2026 | 03-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $751.20 |
| P/E Ratio | $597.67 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $234.92 | $2.94 |
| 52 Week High | $483.60 | $7.98 |
| Indicator | BH | IVA |
|---|---|---|
| Relative Strength Index (RSI) | 69.83 | 31.68 |
| Support Level | $299.54 | $3.77 |
| Resistance Level | $362.62 | $4.67 |
| Average True Range (ATR) | 15.14 | 0.31 |
| MACD | 5.74 | -0.09 |
| Stochastic Oscillator | 98.79 | 8.17 |
Biglari Holdings Inc is a holding company that owns subsidiaries in a range of businesses. The company's reportable segments include Restaurant Operations, Insurance Operations, and Oil and Gas Operations. Its restaurant operations include Steak n Shake and Western Sizzlin. Its insurance operations include First Guard, Southern Pioneer, and Biglari Reinsurance. Oil and gas operations include Southern Oil and Abraxas Petroleum. The company also reports segment information for Maxim. The majority of revenue is derived from the Restaurant Operations Segment.
Inventiva SA is a France-based clinical-stage biopharmaceutical company focused on the development of oral small-molecule therapies for the treatment of MASH. The wholly-owned research and development facility and a team with expertise and experience in the development of compounds that target nuclear receptors, transcription factors and epigenetic modulation. Leveraging the expertise, the company is also advancing lanifibranor for the treatment of MASH and has a pipeline of earlier-stage therapeutic programs in oncology. It operates in the segment of Service delivery and clinical stage research, notably into therapies in the areas of oncology, fibrosis, and rare diseases. All the company's operations are in France.